PAVmed Inc.
PAVM- Exchange
- Nasdaq
- Industry
- Surgical & Medical Instruments & Apparatus
- SEC CIK
- 0001624326
No open-market purchases or sales by PAVmed Inc. insiders were filed in the last 90 days; 20 institutions reported holding it in 13F filings for Q2 2026, worth $5.56M in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 16, 2026
- $14.0M
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, 0 vs. previous quarter
- 20
- 13F valueReported value at the end of Q2 2026
- $5.56M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $71.0K
- −97.6% year over year
- Net income, FY2025
- $401.0K
- −99.0% year over year
- Free cash flow, FY2025
- -$5.24M
- No comparable prior period
- Revenue, Q3 FY2026
- $41.0K
- +720.0% year over year
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 12.8K
- Shares sold short
- Change
- +95
- +0.8% vs. previous
- Days to cover
- 1.04
- At average daily volume
Superinvestors holding PAVM, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding PAVM at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by PAVmed Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Dec 7, 2022 (view filing) | Dec 5 | 2 days | Glennon Michael JDirector | PPurchase | +62.0K | $0.69 | +$42.8K | New position62.0K after | |
| Dec 7, 2022 (view filing) | Dec 6-7 | 1 day | Glennon Michael JDirector | PPurchase | +188.0K | $0.6294 | +$118.3K | +303.2%250.0K after | 2 lots |
Top 10 13F holders, Q2 2026
See all 20 holdersThe largest institutional positions in PAVmed Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Two Seas Capital LP | 461,539 | $2.74M | 0.10% | 00.0% | Unchanged |
| First Manhattan Co | 332,911 | $1.98M | 0.01% | +309,106+1,298.5% | Added |
| Vanguard Capital Management LLC | 61,604 | $365.9K | 0.00% | +55,687+941.1% | Added |
| Geode Capital Management, LLC | 36,678 | $217.9K | 0.00% | +24,901+211.4% | Added |
| Vanguard Fiduciary Trust Co | 25,605 | $152.1K | 0.00% | +20,176+371.6% | Added |
| BlackRock, Inc. | 17,092 | $101.5K | 0.00% | +14,676+607.5% | Added |
| Morgan Stanley | 163 | $968 | 0.00% | −2−1.2% | Reduced |
| Barclays PLC | 75 | $446 | 0.00% | +75 | New |
| SBI Securities Co., Ltd. | 67 | $398 | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 57 | $339 | 0.00% | −18−24.0% | Reduced |
Holders of 5% or more of PAVM
See all 9 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of PAVmed Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Tasso Partners, LLC | 13G/A | 15.30%974.2K shares | +1.00 ppfrom 14.30% | Feb 28, 20253 filings | Apr 14, 2026 | SEC |
| Ayrton Capital LLC | 13G/A | 9.99%709.1K shares | +0.09 ppfrom 9.90% | Feb 14, 20243 filings | May 11, 2026 | SEC |
| Two Seas Capital LP | 13G | 9.99%657.2K shares | New | May 15, 20261 filing | May 15, 2026 | SEC |
| Scopia Holdings LLC | 13G | 9.90%637.7K shares | New | Apr 13, 20261 filing | Apr 13, 2026 | SEC |
| First Manhattan Co | 13G | 9.60%639.2K shares | +5.30 ppfrom 4.30% | Nov 14, 20243 filings | May 14, 2026 | SEC |